Skip to content

Lufwanyama Neonatal Survival Project

Lufwanyama Neonatal Survival Project

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00518856
Acronym
LUNESP
Enrollment
3559
Registered
2007-08-21
Start date
2006-09-30
Completion date
2009-07-31
Last updated
2011-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mortality

Keywords

birth asphyxia, neonatal sepsis, maternal to child transmission of HIV

Brief summary

We seek to determine whether we can reduce day 28 mortality in Zambian newborns by training traditional birth attendants a modified version of the neonatal resuscitation protocol (NRP) and by improving their abiltiy to identify sepsis and initiate antibiotics in the field.

Detailed description

This is a cluster randomized trial of the impact of providing additional training and supplies to traditional birth attendants in a rural setting in Zambia. 120 TBAs are randomized into intervention/control. Intervention TBAs receive NRP training, supplies for neonatal resuscitation, receiving blankets for thermoregulation, and amoxicillin tablets. Control TBAs continue according to prior standard of care. Primary outcome is mortality at 28 days life as a proportion of births attended by TBAs in each study arm.

Interventions

OTHERNeonatal resuscitation protocol

training in neonatal resuscitation and sepsis identification early treatment

OTHERStandard of care

continued with current standard of care for birth attendants

Sponsors

Tufts University
CollaboratorOTHER
Boston University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* TBA trained in safe delivery; * willing to sign informed consent; willing to be randomized; willing to adhere to study procedures

Exclusion criteria

* TBA living outside of Lufwanyama district

Design outcomes

Primary

MeasureTime frame
mortalityday 28

Secondary

MeasureTime frame
perinatal mortalityday zero
sepsis mortalitydeaths between days 1-28
cost effectivenessdays 0-28
successful delivery of nevirapine prophylaxis to HIV exposed deliveriesday zero umbilical cord dried blood spot

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026